This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Elizabeth Knoll, PhD
University of California Press Los Angeles

JAMA. 1989;261(16):2330.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor. —

After months of widely publicized investigation, psychologist Stephen Breuning has admitted recently (in court) to having invented a great deal of data supporting the use of methylphenidate (Ritalin) to control hyperactivity in severely retarded children.¹ Robert Sprague, the former colleague of Breuning who first discovered and reported the fraud, calculated that between 1979 and 1983 Breuning's publications accounted for slightly more than one third of the published research in the psychopharmacology of mental retardation.² Several states depended largely on his publications in setting regulations for the treatment of the institutionalized mentally retarded.¹

The October 21 issue of JAMA contains one letter to the editor and two articles on the possibly excessive use of medication—particularly methylphenidate hydrochloride—in the treatment of attention-deficit hyperactivity disorder.^3-5 Understandably, since specialists in attention-deficit hyperactivity disorder know of Breuning's fraud, none of the articles cited Breuning. Granted, they did . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?